Search

You searched for "endothelium"

408 results found

Ocular toxicity secondary to deferoxamine

12 June 2026 | | EYE - Pathology, EYE - Imaging, EYE - Vitreo-Retinal
Patients with myelodysplastic syndromes can develop transfusion-related iron overload as they become dependent on recurrent blood transfusions [1]. Iron chelation therapy is indicated for the treatment of iron overload and one established example of this is deferoxamine. However, deferoxamine ocular...

The results of the last survey Dec20

7 December 2020 | | EYE - Cataract, EYE - Refractive, EYE - General
The responses to the first question in this survey demonstrate the need for it and the significant variation in practice we see in even relatively simple management decisions. Patients are seen regularly with occludable drainage angles and listed for YAG...

Can OCT predict Alzheimer’s disease?

5 February 2020 | | EYE - Imaging, EYE - General
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Can OCT predict Alzheimer’s disease? In 1986 Hinton et al. demonstrated evidence of optic nerve degeneration...

A case of ‘60-day glaucoma’

3 April 2023 | | EYE - General
Neovascular glaucoma (NVG) has been called ‘90-’ or ‘100-day glaucoma’ in the past due to its typical development three months after the onset of central retinal vein occlusion (CRVO). In reality, NVG can occur anywhere between two weeks and two...

Do steroids prevent progression to proliferative diabetic retinopathy (PDR)?

1 February 2017 | | EYE - Vitreo-Retinal
There is continuing debate on the merits of pan-retinal photocoagulation (PRP) for severe pre-proliferative and proliferative DR versus the newer therapies that inhibit vascular endothelial growth factor (VEGF). This has been hotly debated [1] following the publication of findings from...

Running a high-volume nurse led intravitreal service using the Sp.eye device – the Stanley Eye Unit experience

2 February 2024 | | EYE - Vitreo-Retinal
Introduction The vast majority of ophthalmology units utilise allied healthcare professionals (AHPs) to deliver intravitreal injections (IVIs). The Royal College of Ophthalmologists issued a statement 10 years ago advocating the use of non-medical practitioners performing IVIs [1]. The main benefit...

My Top Five: Promising gene therapies for ocular conditions

4 December 2024 | | EYE - Vitreo-Retinal
Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

My Top Five: Promising gene therapies for ocular conditions

4 December 2024 | | EYE - Vitreo-Retinal
Gene therapy, a pivotal advancement in modern medicine, particularly shines in ophthalmology. By targeting defective genes with engineered vectors, this approach promises significant strides in treating inherited retinal diseases. This article reviews the top five gene therapies in late-stage trials,...

My Top Five: Visionary inventions in ophthalmology

3 April 2026 | | EYE - General
When we see how technologically forward and advanced modern-day medicine is, we forget that it is also an age-old, ancient profession with a rich, intriguing history that we remain unaware of. Ophthalmology in particular has always been at the forefront...

Strategies for managing neovascular AMD and DMO in routine clinical care

1 October 2015 | | EYE - Vitreo-Retinal
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

Broadening of treatment options for potentially blinding retinal conditions

2 August 2022 | | EYE - General
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Treatment of diabetic macular oedema

1 June 2014 | | EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...